𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors

✍ Scribed by Lisa M. McGregor; Sheri L. Spunt; Victor M. Santana; Clinton F. Stewart; Deborah A. Ward; Amy Watkins; Fred H. Laningham; Percy Ivy; Wayne L. Furman; Maryam Fouladi

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
197 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II study of daily oral etoposide i
Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors
✍ Needle, Michael N.; Molloy, Patricia T.; Geyer, J. Russell; Herman-Liu, Alisa; B πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 315 KB πŸ‘ 2 views

Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of or

Phase I study of a 120-hour continuous i
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study
✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

Phase I study of fotemustine in pediatri
Phase I study of fotemustine in pediatric patients with refractory brain tumors
✍ Darren R. Hargrave; Eric Bouffet; Janet Gammon; Nauman Tariq; Ron M. Grant; Sylv πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 184 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Fotemustine is a nitrosourea with theoretic and preclinical advantages over the original analogs, carmustine and lomustine, in the treatment of brain tumors. This is the first pediatric Phase I study of fotemustine. ## METHODS Patients younger than 21 with recurrent/res